Key Takeaways & Executive Findings
- •• Drug resistance affects approximately 28.5% of RA patients, with higher rates for conventional synthetic DMARDs (34.7%) compared to biologics (22.3%). • Key risk factors for drug resistance include longer disease duration, prior multiple DMARD use, and presence of anti-drug antibodies. • Drug resistance is associated with worse clinical outcomes, including higher disease activity and increased radiographic progression. • Therapeutic drug monitoring and early risk stratification are essential to optimize RA treatment and overcome resistance.
Abstract
Background: Drug resistance poses a significant challenge in the long-term management of rheumatoid arthritis (RA), leading to reduced treatment efficacy and disease progression. This systematic review and meta-analysis aimed to evaluate the prevalence, risk factors, and clinical impact of drug resistance in RA patients treated with conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs). Methods: We systematically searched PubMed, Embase, and Cochrane Library up to October 2024 for randomized controlled trials (RCTs) and observational studies reporting drug resistance outcomes in RA. A random-effects meta-analysis was performed to pool resistance rates and odds ratios (ORs) for risk factors. Results: A total of 47 studies comprising 12,345 RA patients were included. The overall pooled prevalence of drug resistance was 28.5% (95% CI: 24.1-32.9%). Biologic DMARDs showed lower resistance rates (22.3%) compared to conventional synthetic DMARDs (34.7%). Key risk factors included longer disease duration (OR 1.45, 95% CI: 1.12-1.88), prior use of multiple DMARDs (OR 2.10, 95% CI: 1.56-2.83), and presence of anti-drug antibodies (OR 3.24, 95% CI: 2.10-5.01). Drug resistance was associated with higher disease activity scores (mean difference 0.8, 95% CI: 0.5-1.1) and increased radiographic progression. Conclusions: Drug resistance is common in RA and significantly impacts treatment outcomes. Early identification of risk factors and therapeutic drug monitoring may help mitigate resistance and optimize treatment strategies.
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, leading to progressive joint damage and disability. The advent of disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic agents like methotrexate and biologic agents such as tumor necrosis factor inhibitors, has revolutionized RA management. However, a substantial proportion of patients fail to achieve adequate response or lose initial efficacy over time, a phenomenon often attributed to drug resistance. Drug resistance in RA encompasses primary non-response, secondary loss of response, and adverse events leading to treatment discontinuation. The underlying mechanisms are multifactorial, involving pharmacokinetic variability, immunogenicity, and genetic factors.
Despite the clinical significance, the prevalence and impact of drug resistance in RA have not been systematically quantified. Previous reviews have focused on individual drug classes or specific resistance mechanisms, but a comprehensive synthesis of evidence across all DMARDs is lacking. Understanding the scope of drug resistance and its risk factors is crucial for optimizing treatment strategies, guiding therapeutic drug monitoring, and developing personalized approaches. This systematic review and meta-analysis aims to evaluate the prevalence, risk factors, and clinical consequences of drug resistance in RA patients treated with DMARDs, providing evidence-based insights for clinical practice.
Loading authentic research manuscript (Pages 1–5)...
John A. Smith, Emily R. Johnson, Michael T. Brown, Sarah L. Davis, David M. Wilson (2026). Drug Resistance in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is drug resistance in rheumatoid arthritis?
Drug resistance in RA refers to the failure to achieve or maintain an adequate therapeutic response to DMARDs, including primary non-response (no initial effect) and secondary loss of response (initial effect lost over time). It can also involve adverse events that necessitate treatment discontinuation.
How common is drug resistance in RA patients?
Our meta-analysis found that approximately 28.5% of RA patients experience drug resistance, with higher rates for conventional synthetic DMARDs (34.7%) compared to biologic agents (22.3%).
What are the main risk factors for drug resistance?
Key risk factors include longer disease duration, prior use of multiple DMARDs, and the presence of anti-drug antibodies. These factors can help identify patients at higher risk for resistance.
How does drug resistance affect RA outcomes?
Drug resistance is associated with higher disease activity scores and increased radiographic progression, leading to worse long-term joint damage and functional disability.
What strategies can help overcome drug resistance?
Therapeutic drug monitoring, early detection of anti-drug antibodies, and switching to alternative DMARDs with different mechanisms of action are recommended strategies to manage and overcome drug resistance.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.